Bioaffinity Technologiew-27BIAFWPreferred / convertible
13F holders, Q2 2025 (June 30)4holders
0new positions
0sold out
1famous investor
$0.13avg. 13F price*
At the end of Q2 2025, 4 institutions reported holding Bioaffinity Technologiew-27 (BIAFW) in their 13F filings, unchanged from Q1 2025. 0 opened new positions and 0 sold out. The largest holders were Armistice Capital, LLC ($27K), Clear Street LLC ($7K) and UBS Group AG ($6K). One famous investor held it Ken Griffin ( of Citadel Advisors's portfolio).
- Company
- Bioaffinity Technologiew-27
- CUSIP
- 09076W117
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q1 2025 → Q2 2025: 289 shares bought and 3,633 shares sold, net −3,344 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Armistice Capital, LLC | — | No change | 204,082 | $27K |
| Clear Street LLC | — | No change | 55,122 | $7K |
| UBS Group AG | — | Add +0.6% | 48,572 | $6K |
| Citadel Advisors | — | Reduce -10.1% | 32,355 | $4K |
"% of holder's portfolio" is BIAFW's weight in each manager's 13F, not the share of Bioaffinity Technologiew-27 the manager owns.